Open Menu Close Menu Open Search Close Search Open Directory Close Directory

Kristine E Burgess - DVM, MLA, DACVIM

Kristine E Burgess

Campus Phone:

508-839-7922 or 7951

Dr. Kristine Burgess is a board certified veterinary oncologist at the Foster Hospital for Small Animals. In her position at the Cummings School, Dr. Burgess loves the diverse mix of teaching, research and clinical service that comprise her position. She takes pleasure in working directly with fourth-year students and residents during their clinical rotations within the Foster Hospital for Small Animals, and is grateful for the opportunity to shape the future of veterinary students and residents in their careers as veterinarians and veterinary specialists.

Growing up outside of Boston, Dr. Burgess had her sights set on veterinary medicine but, after completing her bachelor’s degree, instead engaged in laboratory research at the world-renowned Dana Farber Cancer Institute in Boston and the Netherlands Cancer Institute in Amsterdam. These experiences were instrumental in affirming her interests in cancer research and medicine. She merged that with her passion for veterinary medicine by earning her DVM from the Cummings School at Tufts University, completing her residency training at the University of Wisconsin, then rejoining Tutfs as faculty.

At the Cummings School Dr. Burgess is grateful for the opportunity to offer our cancer patients top-notch, state-of-the-art and compassionate care, including conventional and novel chemo- or immunotherapies. For each individual patient, Dr. Burgess provides information on all treatment options with the ultimate goal of achieving an excellent quality of life for as long as possible. She firmly believes “knowledge is power” and everyone benefits when informed decisions are made in the best interests of the pet.

Similar to human oncology, there is a great deal of variability in outcome when treating different forms of cancer, but regardless of the treatment path, there is no better feeling than making a difference in the life of an animal and their owner family. This is the most rewarding aspect of being a veterinary oncologist for her.

Dr. Burgess lives with her husband, daughter, son, two dogs, many cats and one fish. This menagerie counts as part of the extended family and she enjoys time spent, especially being outdoors, with all of them (except the fish).


  • DVM - Tufts University - 1997
  • Harvard University Masters of Liberal Arts Extension Studies, Concentration in Science – 1991
  • BS - University of Massachusetts - 1988

Board Certification

  • American College of Veterinary Internal Medicine - Oncology
  • Dr. Burgess is currently seeking additional training in the field of radiation oncology
  1. Saba, C.F., Clifford, C., Burgess, K., Phillips, B., Vail, D., Wright, Z., Curran, K., Fan, T., Elmslie, R., Post, G., Thamm, D. 2020. Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. Veterinary and Comparative Oncology.
  2. Lew, F.H., McQuown, B., Borrego, J., Cunningham, S., Burgess, K.E. 2019. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018. Veterinary and Comparative Oncology.
  3. Webb, J.K., Graham, J.E., Burgess, K.E., Antinoff, N. 2019. Presentation and survival time of domestic ferrets (Mustela putorius furo) with lymphoma treated with single- and multiagent protocols: 44 cases (1998–2016). Journal of Exotic Pet Medicine.
  4. Burgess, K.E., DeRegis, C.J. 2019. Urologic Oncology. Veterinary Clinics of North America - Small Animal Practice.
  5. McQuown, B., Burgess, K.E., Heinze, C.R. 2018. Preliminary investigation of blood concentrations of insulin-like growth factor, insulin, lactate and β-hydroxybutyrate in dogs with lymphoma as compared with matched controls. Veterinary and Comparative Oncology.
  6. McDonald, J.T., Kritharis, A., Beheshti, A., Pilichowska, M., Burgess, K., Ricks-Santi, L., McNiel, E., London, C.A., Ravi, D., Evens, A.M. 2018. Correction: Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel [Oncotarget., 9, (2018) (22693-22702)] doi: 10.18632/oncotarget.25209. Oncotarget.
  7. McDonald, J.T., Kritharis, A., Beheshti, A., Pilichowska, M., Burgess, K., Ricks-Santi, L., McNiel, E., London, C.B., Ravi, D., Evens, A.M. 2018. Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget.
  8. Saba, C.F., Vickery, K.R., Clifford, C.A., Burgess, K.E., Phillips, B., Vail, D.M., Wright, Z.M., Morges, M.A., Fan, T.M., Thamm, D.H. 2018. Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses. Veterinary and Comparative Oncology.
  9. Burgess, K.E., Case, A. 2018. The authors respond. Journal of the American Veterinary Medical Association.
  10. Sogame, N., Risbon, R., Burgess, K.E. 2018. Intestinal lymphoma in dogs: 84 cases (1997–2012). Journal of the American Veterinary Medical Association.
  11. Case, A., Burgess, K. 2018. Safety and efficacy of intralesional triamcinolone administration for treatment of mast cell tumors in dogs: 23 cases (2005-2011). Journal of the American Veterinary Medical Association.
  12. Wilson-Robles, H., Budke, C.M., Miller, T., Dervisis, N., Novosad, A., Wright, Z., Thamm, D.H., Vickery, K., Burgess, K., Childress, M., Lori, J., Saba, C., Rau, S., Silver, M., Post, G., Reeds, K., Gillings, S., Schleis, S., Stein, T., Brugmann, B., DeRegis, C., Smrkovski, O., Lawrence, J., Laver, T. 2017. Geographical differences in survival of dogs with non-Hodgkin lymphoma treated with a CHOP based chemotherapy protocol. Veterinary and Comparative Oncology.
  13. Rau, S.E., Burgess, K.E. 2017. A retrospective evaluation of lomustine (CeeNU) in 32 treatment naïve cats with intermediate to large cell gastrointestinal lymphoma (2006–2013). Veterinary and Comparative Oncology.
  14. McQuown, B., Keyerleber, M.A., Rosen, K., McEntee, M.C., Burgess, K.E. 2017. Treatment of advanced canine anal sac adenocarcinoma with hypofractionated radiation therapy: 77 cases (1999–2013). Veterinary and Comparative Oncology.
  15. Mullin, C.M., Arkans, M.A., Sammarco, C.D., Vail, D.M., Britton, B.M., Vickery, K.R., Risbon, R.E., Lachowicz, J., Burgess, K.E., Manley, C.A., Clifford, C.A. 2016. Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs†. Veterinary and Comparative Oncology.
  16. Palladino, S., Keyerleber, M.A., King, R.G., Burgess, K.E. 2016. Utility of Computed Tomography versus Abdominal Ultrasound Examination to Identify Iliosacral Lymphadenomegaly in Dogs with Apocrine Gland Adenocarcinoma of the Anal Sac. Journal of Veterinary Internal Medicine.
  17. Burgess, K.E., Deregis, C.J., Brown, F.S., Keating, J.H. 2016. Histologic and immunohistochemical characterization of thymic epithelial tumours in the dog. Veterinary and Comparative Oncology.
  18. Saba, C., Paoloni, M., Mazcko, C., Kisseberth, W., Burton, J.H., Smith, A., Wilson-Robles, H., Allstadt, S., Vail, D., Henry, C., Lana, S., Ehrhart, E.J., Charles, B., Kent, M., Lawrence, J., Burgess, K., Borgatti, A., Suter, S., Woods, P., Gordon, I., Vrignaud, P., Khanna, C., LeBlanc, A.K. 2016. A comparative oncology study of iniparib defines its pharmacokinetic profile and biological activity in a naturally-occurring canine cancer model. PLoS ONE.
  19. Wendelburg, K.M., Price, L.L., Burgess, K.E., Lyons, J.A., Lew, F.H., Berg, J. 2015. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001–2012). Journal of the American Veterinary Medical Association.
  20. Tonomura, N., Elvers, I., Thomas, R., Megquier, K., Turner-Maier, J., Howald, C., Sarver, A.L., Swofford, R., Frantz, A.M., Ito, D., Mauceli, E., Arendt, M., Noh, H.J., Koltookian, M., Biagi, T., Fryc, S., Williams, C., Avery, A.C., Kim, J.-H., Barber, L., Burgess, K., Lander, E.S., Karlsson, E.K., Azuma, C., Modiano, J.F., Breen, M., Lindblad-Toh, K. 2015. Genome-wide Association Study Identifies Shared Risk Loci Common to Two Malignancies in Golden Retrievers. PLoS Genetics.

General Research Interests

  • Understanding the molecular mechanisms that trigger the development of canine/feline cancer and applying those findings into improved diagnostic capabilities and therapeutic options for treatment
  • Participating in clinical trials that evaluate the use of novel chemotherapeutics and immunotherapies in various malignancies

Research Interests by Area

Spontaneous Animal Disease Models
  • Lymphoma, osteosarcoma, transitional cell carcinoma, prostatic cancer, hemangiosarcoma, mammary (breast) cancer, squamous cell carcinoma in cats

Research Interests by Organ System and Disease

Oncology and Cancer Research and Clinical Trials
  • Genetic mapping of canine B cell lymphoma. Clinical oncology, spontaneous animal disease models of cancer, clinical trials